|Tested species reactivity||Rat|
|Published species reactivity||Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide corresponding to the C-terminal region of rat GRM5 conjugated to KLH|
|Storage buffer||0.01M HEPES, pH 7.5, with 0.15M NaCl, 100µg/ml BSA, 50% glycerol|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Dot blot (DB)||1:1000|
|Western Blot (WB)||1:1000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry - Free Floating (IHC (Free))||See 1 publications below|
This antibody is predicted to react with human and mouse based on 100% sequence homology.
This antibody is specific for the ~125 kDa monomer and the ~250 kDa dimmers of mGluR5 and mGluR1 in Western blots of rat brain extracts. Immunolabeling blocked by preadsorption of antibody with the peptide used to generate the antibody.
The metabotropic glutamate receptors (mGluRs) are key receptors in the modulation of excitatory synaptic transmission in the central nervous system. They are implicated in many forms of neural plasticity as well as learning and memory and drug abuse (Bhattacharya et al., 2004; Francesconi et al., 2004; Wilson and Nicoll, 2001). Group I metabotropic glutamate receptors (consisting of mGluR1 and mGluR5) are G-protein-coupled neurotransmitter receptors that are localized in the perisynaptic region of the postsynaptic membrane. When activated, Group I mGluRs lead to stimulation of phospholipase and activation of Protein Kinase C. In contrast activation of Group II metabotropic receptors (mGluR2 and mGluR3) leads to inhibition of adenylate cyclase. The mGluR receptor may also be critically involved in limiting the deleterious effects on excitoxicity (Blaabjerg et al., 2003). In contrast, the mGluR5 receptor appears to be essential for late phase LTP in area CA of the hippocampus (Francesconi et al., 2004).
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Oral administration of the p38¿ MAPK inhibitor, UR13870, inhibits affective pain behavior after spinal cord injury.
PA1-4663 was used in immunohistochemistry - free floating to test the effect of a p38alpha MAPK inhibitor on spinal cord injury in the rat
|Galan-Arriero I,Avila-Martin G,Ferrer-Donato A,Gomez-Soriano J,Bravo-Esteban E,Taylor J||Pain (155:2188)||2014|